Xi Jinping’s Potential India Visit: What We Know
Chinese President Xi Jinping is expected to travel to New Delhi in September for the BRICS summit, his first visit to India since the deadly 2020 Galwan Valley clash plunged bilateral ties to their lowest point in decades. While no official announcement has been made, Indian officials have extended an invitation and Beijing has publicly endorsed India’s presidency of the group.
The summit is scheduled for September 12–13. A Chinese foreign ministry spokesperson said Beijing “attaches great importance to and actively participates in BRICS cooperation” and supports India in making the event a “full success.” The language, while diplomatic, is being read as a signal that Xi will attend.
The BRICS bloc has expanded significantly since its original five members—Brazil, Russia, India, China, and South Africa—first convened. In 2024 it added Egypt, Ethiopia, Iran, and the United Arab Emirates; Indonesia joined in 2025. Kremlin officials have confirmed that Russian President Vladimir Putin will travel to New Delhi, and Bangladesh is considering a high-level presence. Iran has yet to announce the level of its delegation.
Xi last visited India in October 2019 for an informal summit with Prime Minister Narendra Modi in Mamallapuram. Modi himself made his first trip to China in nearly seven years in 2025, attending the Shanghai Cooperation Organisation summit in Tianjin. A reciprocal visit by Xi would restore a degree of top-level engagement that has been absent for over three years.
Geopolitical and Economic Implications of a China-India Thaw
Xi’s Calculated Appearance
Xi’s presence cannot be separated from the border standoff that followed the Galwan incident. The Indian military has been locked in a long-running deployment along the Line of Actual Control (LAC), and disengagement talks have progressed only in fits and starts. Attending the summit does not automatically resolve those tensions, but it would signal that both governments see value in insulating economic and diplomatic tracks from the military friction.
BRICS as a Diplomatic Stage
This year’s summit arrives as the bloc seeks to position itself as a counterweight to Western-led institutions. China’s visible support for India’s chairmanship—especially after the acrimony of 2020—creates political space for other agenda items, such as expanding local-currency trade settlements and development finance through the New Development Bank. A photo of Xi and Modi together would carry more weight than any joint communiqué.
Bilateral Trade and Investment in the Balance
Two-way trade has remained remarkably resilient, exceeding $100 billion annually despite political strains, but it is heavily lopsided in China’s favor. Indian restrictions on Chinese apps, investment screening rules introduced after Galwan, and visa hurdles have chilled business sentiment. A summit handshake could prompt a review of some of these barriers, especially if accompanied by confidence-building measures along the border. However, Indian industry remains wary, and any relaxation would likely be slow and conditional.
Military Tensions and the LAC Dynamic
The summit does not take place in a vacuum. The last disengagement from Depsang and Demchok was hard-won, and further friction points remain. If Xi travels to New Delhi while standoffs persist, it would underscore Beijing’s preference for managing the border as a separate, contained issue—a view India has been reluctant to accept. The risk of a provocation during or just after the summit is low but not zero, and markets will likely price in the continued uncertainty.
What This Means for Businesses and Investors
- Indian firms reliant on Chinese supply chains—especially in electronics, pharmaceuticals, and auto components—should watch the joint statement on September 13. Any explicit mention of trade facilitation or visa easing would be a concrete signal to accelerate contingency planning for smoother flows.
- Investors in Indian manufacturing and infrastructure may see a short-term sentiment boost if the summit produces a joint appearance without negative headlines. Stocks with China-linked revenue or cost exposures could react to a perceived de-risking of geopolitical risk.
- Companies in the technology and digital services sectors should temper expectations. Indian restrictions on Chinese apps and investment screening are deeply institutionalized; a single summit will not unwind them, though it could open a channel for sector-specific dialogue later.
- Multinationals with operations in both countries should use the summit as a trigger to refresh their scenario planning for the bilateral relationship. The September 12–13 window is a indicator of whether high-level diplomacy can provide a predictable floor under the business environment.
Risk & Opportunity Assessment
| Commercial Risk | Medium | Bilateral trade remains large but faces persistent non-tariff barriers and political headwinds. An absent or frosty summit could worsen sentiment, while a successful one might ease some frictions. |
| Competitive Risk | Medium | Indian firms competing with Chinese imports or reliant on Chinese technology face regulatory uncertainty. A thaw could benefit key sectors, but a lack of progress would sustain existing asymmetries. |
| Regulatory Risk | High | India’s restrictions on Chinese apps, investment screening, and defense procurement are shaped by bilateral tensions. Any incident at the summit or along the LAC could trigger new restrictive measures. |
| Reputation Risk | Medium | Indian companies heavily integrated with Chinese supply chains may face domestic pressure if border tensions escalate again. A high-profile diplomatic engagement helps normalise business links. |
| Technology Disruption | Low | Technology restrictions are already in place, and the summit is unlikely to alter the strategic decoupling in critical tech sectors such as 5G and semiconductors. |
| Commercial Opportunity | Medium | A successful summit could create permission for incremental cooperation in sectors like electric vehicles, renewable energy, and pharma, especially if accompanied by a border disengagement deal. |
Comments 0